DOI: 10.1055/s-00000069

Seminars in Liver Disease

References

Christensen B, Micic D, Gibson PR. , et al.
Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease.

Aliment Pharmacol Ther 2018;
47 (06) 753-762

Christensen B, Micic D, Gibson PR. , et al.
Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease.

Aliment Pharmacol Ther 2018;
47 (06) 753-762

Download Bibliographical Data

Search in:
Access: